When to Start Levodopa Therapy for Parkinsons Disease
NEJM 380:389-390, Bressman, S. & Saunders-Pullman, R., 2019
What Contributes to Quality of Life in Patients with Parkinson's Disease?
JNNP 69:308-312,289, Schrag,A. et al, 2000
Efficacy, Safety, and Tolerance of the Non-Ergoline Dopamine Agonist Pramipexole in the Treatment of Advanced Parkinson's Disease:A Double Blind, Placebo Controlled, Randomised, Multicentre Study
JNNP 66:436-441, Pinter,M.M.,et al, 1999
Assessment of Motor Function After Stereotactic Pallidotomy
Neurol 50:266-270, Ondo,W.G.,et al, 1998
Practice Styles of US Compared to UK Neurologists
Neurol 50:1661-1668, Vickrey,B.G.,et al, 1998
Neuropsychological Consequences of Posteroventral Pallidotomy for the Treatment of Parkinson's Disease
Neurol 51:207-215, Trepanier,L.L.,et al, 1998
Cognitive Functioning After Pallidotomy for Refractory Parkinson's Disease
JNNP 65:150-154, 1481998., Perrine,K.,et al, 1998
Parkinson's Disease
JNNP 57:672-681, Marsden,C.D., 1994
Early Development of Levodopa-Induced Dyskinesias and Response Fluctuations in Young-Onset Parkinson's Disease
Neurol 41:202-205, Kostic,V., 1991
Does Ageing Aggravate Parkinsonisn Disability?
JNNP 54:780-782, Blin,J.,et al, 1991
Mortality Associated with Early and Late Levodopa Therapy Initiation in Parkinson's Disease
Neurol 40:265-269, Scigliano,G.,et al, 1990
Does Levodopa Aggravate Parkinson's Disease
Neurol 38:1410-1416, Blin,J.,et al, 1988
Factors that Influence the Occurrence of Response Variations in Parkinson's Disease
Ann Neurol 22:4-7, deJong,G.J.,et al, 1987
Multi-Center Study of Parkinson Mortality with Early Versus Later Dopa Treatment
Ann Neurol 22:8-12, Diamond,S.G.,et al, 1987